All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

ADCs and Immunotherapy Are Redefining Urothelial Cancer Treatment

December 21st 2023

Bupathi highlights key points that were presented at an OncLive Institutional Perspectives in Cancer, including implications of the EV-302 trial findings; data updates from the phase 1/2 ICRA trial; and future directions for urothelial cancer.

FDA Grants Breakthrough Therapy Designation to BNT323/DB-1303 in Endometrial Cancer

December 21st 2023

The FDA has granted breakthrough therapy designation to the HER2-targeted antibody-drug conjugate BNT323/DB-1303 for use as a potential therapeutic option in patients with advanced endometrial cancer who have progressed on or after treatment with immune checkpoint inhibitors.

Cancer Blood Tests Jumpstart Diagnoses and Targeted Therapy

December 21st 2023

New research led by a UC Davis Comprehensive Cancer Center clinical scientist shows blood tests used to hunt for cancer DNA may help detect cancers faster and guide the use of targeted therapies.

sBLA and NDA Submitted to FDA for Amivantamab and Lazertinib in EGFR-Mutant NSCLC

December 21st 2023

A supplemental biologics license application and new drug application seeking the approval of amivantamab plus lazertinib as frontline therapy for the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations have been submitted to the FDA.

B7-H4 Offers Potential Treatment Target in a Variety of Solid Tumors

December 21st 2023

The transmembrane protein B7-H4 has emerged as an interesting therapeutic target in multiple solid tumors, with investigators mostly focusing on the development of antibody-drug conjugates aimed at the pathway.

ESR1 Coalteration Treatment Resistance Does Not Impact Lasofoxifene/Abemaciclib Efficacy in ESR1+ Metastatic Breast Cancer

December 21st 2023

The presence of ESR1 coabnormalities, including TP53 and PIK3CA mutations, and CCND1 and FGFR1 amplification, did not demonstrate a negative impact on the efficacy with lasofoxifene and abemaciclib in patients with estrogen receptor–positive, ESR1-mutant metastatic breast cancer.

European Commission Approves New Frontline Indications for Pembrolizumab Plus Chemo in Select GI Cancers

December 21st 2023

The European Commission has approved new indications for pembrolizumab in combination with chemotherapy in select patients with gastric or gastroesophageal adenocarcinoma and select patients with biliary tract cancer.

Quality of Life, Toxicity Weighed Most by Patients When Choosing Metastatic Breast Cancer Treatment

December 20th 2023

Quality of life and adverse effects are key components most patients with estrogen receptor–positive, HER2-negative metastatic breast cancer weigh when choosing an anticancer therapy, according to patient-reported results of an ESR1 QUAlity of Life Survey 3 survey.

Zanubrutinib Improves PFS in Treatment-Naive CLL/SLL, Regardless of Complex Karyotypes

December 20th 2023

Paolo Ghia, MD, PhD, describes the various cohorts of the SEQUOIA study, expands on outcomes from a biomarker subgroup analysis with zanubrutinib vs bendamustine plus rituximab, and more.

New Precision Medicine and Developmental Therapeutics Cancer Clinic Opens at Allegheny General Hospital

December 20th 2023

The Allegheny Health Network Cancer Institute announced today that it has established one of the region’s first clinics dedicated to precision cancer medicine and has appointed nationally recognized medical oncologist Ariel Lopez-Chavez, MD, MS, to serve as director of the new clinic.

Addition of Tucatinib to Breast Cancer Maintenance Therapy Aims to Fill Unmet Need for Patients With Brain Metastases

December 20th 2023

Tucatinib, which inhibits phosphorylation of HER2/3 resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, has shown promise for patients with brain metastases as the small molecule inhibitor of HER2 can cross the blood-brain barrier.

177Lu-PNT2002 Significantly Improves rPFS Vs ARPI in Metastatic Castration-Resistant Prostate Cancer

December 20th 2023

Treatment with 177Lu-PNT2002 resulted in a significant improvement in radiographic progression-free survival vs abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer whose disease had progressed on an androgen receptor pathway inhibitor.

Dostarlimab Plus Chemo Followed by Dostarlimab/Niraparib Improves PFS in Endometrial Cancer

December 20th 2023

Dostarlimab plus carboplatin and paclitaxel, followed by maintenance dostarlimab and niraparib, significantly improved PFS vs placebo plus chemotherapy followed by placebo in patients with primary advanced or recurrent endometrial cancer, according to data from the phase 3 RUBY trial.

ctDNA Could Aid in Treatment Escalation and De-escalation Decisions in Kidney Cancer

December 19th 2023

Alan Tan, MD, discusses how utilizing circulating tumor DNA may provide valuable insight into when to escalate vs de-escalate treatment for patients with renal cell carcinoma.

Zanubrutinib Continues to Provide PFS Benefit Vs Ibrutinib in Relapsed/Refractory CLL/SLL

December 19th 2023

Jennifer R. Brown, MD, PhD, discusses the clinical implications of the ALPINE study and highlights a subgroup analysis of acquired mutations in patients with chronic lymphocytic leukemia, demonstrating which mutations were associated with resistance to covalent BTK inhibitors.

Non–Clear Cell RCC Subtypes Require Individualized Approach to Treatment Selection

December 19th 2023

Jaime R. Merchán, MD, spotlights case studies of patients with rare non-ccRCC histologies, discussing their clinical presentation, recent data on immunotherapy and targeted treatment options for the management of these disease subtypes, and patient outcomes on these therapies.

Acalabrutinib Triplet Shows Early Signals of Activity, Safety in R/R Mantle Cell Lymphoma

December 19th 2023

The combination regimen comprised of acalabrutinib, venetoclax, and obinutuzumab proved to be safe and feasible and to elicit responses in patients with high-risk, relapsed or refractory mantle cell lymphoma.

Allina Health Cancer Institute Begins First-of-its-Kind Clinical Trial to Revolutionize Cancer Treatment and Diagnosis

December 19th 2023

Allina Health Cancer Institute is collaborating with St. Paul-based Astrin Biosciences for a first-of-its-kind clinical trial using artificial intelligence and a simple blood draw to revolutionize how cancer is diagnosed and treated.

Relma-Cel Continues to Elicit Responses in Chinese Patients With R/R Mantle Cell Lymphoma

December 19th 2023

Relmacabtagene autoleucel continued to induce responses with acceptable tolerability in Chinese patients with relapsed or refractory mantle cell lymphoma.

TP-3654 Demonstrates Favorable Tolerability, Early Clinical Activity in R/R Myelofibrosis

December 19th 2023

The oral selective PIM1 kinase inhibitor TP-3654 appeared to be well tolerated and to show early signals of spleen volume reduction, symptom improvement, and correlating cytokine reductions in patients with relapsed or refractory myelofibrosis, according to preliminary data.